Feline calicivirus (FCV) is one of the most widespread pathogens affecting feline animals. Currently, FCV is believed to be divisible into two genotypes, with prevalent strains encompassing both GI and GII. Vaccination is the primary means of preventing FCV infection, yet traditional inactivated or attenuated vaccines theoretically pose potential safety concerns. In this study, a virus-like particles (VLPs), named DL39-VLPs, was constructed, using the gene of FCV DL39 strain with broad neutralizing and protective properties as a template through insect cell expression system. Cats were immunized with a 50 μg dose of DL39-VLPs mixed with an oily adjuvant via subcutaneous injection in the neck. For feline antisera positive for DL39-VLPs, the titer range in neutralization tests against prevalent GI strains ranged from 1:151 to 1:538, whereas the titer range in neutralization tests against prevalent GII strains was between 1:65 and 1:113. Challenge trials demonstrated that cats immunized with DL39-VLPs exhibited no significant clinical symptoms and had significantly reduced viral shedding and viremia compared to the challenged control group. Ultimately, a safe and highly protective VLP vaccine candidate, DL39-VLPs, was developed, which provides an important tool for the prevention and control of FCV infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695357 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1515342 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Next-generation vaccines for influenza B virus: advancements and challenges.
Arch Virol
January 2025
CAS Key Laboratory of Molecular Virology & Immunology, Institutional Center for Shared Technologies and Facilities, Pathogen Discovery and Big Data Platform, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Yueyang Road 320, Shanghai, 200031, China.
To battle seasonal outbreaks of influenza B virus infection, which continue to pose a major threat to world health, new and improved vaccines are urgently needed. In this article, we discuss the current state of next-generation influenza B vaccine development, including both advancements and challenges. This review covers the shortcomings of existing influenza vaccines and stresses the need for more-effective and broadly protective vaccines and more-easily scalable manufacturing processes.
View Article and Find Full Text PDFAn effectively protective VLP vaccine candidate for both genotypes of feline calicivirus.
Front Immunol
January 2025
State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.
Feline calicivirus (FCV) is one of the most widespread pathogens affecting feline animals. Currently, FCV is believed to be divisible into two genotypes, with prevalent strains encompassing both GI and GII. Vaccination is the primary means of preventing FCV infection, yet traditional inactivated or attenuated vaccines theoretically pose potential safety concerns.
View Article and Find Full Text PDFAra h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals.
J Allergy Clin Immunol
January 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address:
Background: Peanut allergy (PA) is one of the most prevalent food allergies with a lack of favorable safety/efficacy treatment. A cucumber mosaic virus-like particle expressing peanut allergen component Ara h 2 (VLP Peanut) has been developed as a novel therapeutic approach for PA.
Objective: We assessed the tolerogenic properties and reactivity of VLP Peanut.
Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles.
Vaccine
December 2024
Mucosal Immunoogy Laboratory, Biomedicine Research Unit, Faculty of Higher Studies Iztacala, National Autonomous University of Mexico. Avenida de los Barrios 1, Los Reyes Iztacala, Tlalnepantla, Estado de México 54090, Mexico. Electronic address:
The development of a protective HIV vaccine remains a challenge given the high antigenic diversity and mutational rate of the virus, which leads to viral escape and establishment of reservoirs in the host. Modern antigen design can guide immune responses towards conserved sites, consensus sequences or normally subdominant epitopes, thus enabling the development of broadly neutralizing antibodies and polyfunctional lymphocyte responses. Conventional epitope vaccines can often be impaired by low immunogenicity, a limitation that may be overcome by using a carrier system.
View Article and Find Full Text PDFMultifaceted virus-like particles: Navigating towards broadly effective influenza A virus vaccines.
Curr Res Microb Sci
November 2024
Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
The threat of influenza A virus (IAV) remains an annual health concern, as almost 500,000 people die each year due to the seasonal flu. Current flu vaccines are highly dependent on embryonated chicken eggs for production, which is time consuming and costly. These vaccines only confer moderate protections in elderly people, and they lack cross-protectivity; thereby requiring annual reformulation to ensure effectiveness against contemporary circulating strains.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!